Banner background image Banner background image
Banner background image Banner background image
Banner background image Banner background image

SUPPORTING ACCESS

  • FOR YOUR PRACTICE

  • FOR YOUR PATIENTS

  • ACQUIRING LEQVIO®

Your dedicated team provides
sources of support

Visit the LEQVIO Service Center

SERVICE CENTER

SERVICE CENTER

Access Specialist

  • Provide information regarding insurance verification

  • Explain patient affordability solutions

  • Advise on prior authorization research and offer appeals support

  • Address billing support and coding questions

  • Explain patient affordability solutions

Dedicated Access Specialists are available Monday to Friday, 8:00 AM to 8:00 PM (ET).

CALL 1-833-LEQVIO2 (1-833-537-8462)

CALL 1-833-LEQVIO2
(1-833-537-8462)

Field Reimbursement Manager

  • Provide payer coverage information

  • Provide reimbursement support

  • Explain specific product acquisition options for LEQVIO

  • Answer questions regarding patient support program offerings, including co-pay and adherence support

  • Provide information on local payer billing/coding/claim submission policies and procedures

  • Provide reimbursement support

  • Answer questions regarding patient support program offerings, including co-pay and adherence support

Available for in-office visits or by phone. Ask your LEQVIO Sales Specialist
for your Field Reimbursement Manager's contact information.

Available for in-office visits or by phone. Ask your LEQVIO Sales Specialist for your Field Reimbursement Manager's contact information.


Self-Service Website

  • Comprehensive resources on acquisition, affordability, reimbursement, and all patient support programs

  • Alternate Injection Center Locator Tool

  • Live Click-to-Chat

VISIT
LEQVIO-ACCESS.COM arrow
Contact a Sales Specialist Contact a Sales Specialist

SALES SPECIALIST

SALES SPECIALIST

  • Provide clinical product information

  • Sales Specialists do not have access to patient-level data

  • Review general acquisition information

  • Offer information regarding
    co-pay and adherence
    support options

  • Sales Specialists do not have access to patient‑level data

CONTACT A SALES
SPECIALIST arrow

LEQVIO aims to be affordable for your patients

Medicare Part B

Nearly 80% of patients with Medicare Part B fee-for-service coverage also have supplemental (ie, Medigap or secondary) insurance and may pay as little as $0 out-of-pocket for LEQVIO.


Commercial

Eligible commercially insured patients may pay as little as $0 for each LEQVIO treatment with the co‑pay card. Subject to terms and conditions. Limitations apply.*

Eligible commercially insured new patients may be able to receive up to two (2) free doses if coverage is delayed or denied. Subject to terms and conditions. Limitations apply.

LEQVIO co-pay card

For commercially insured patients

*Limitations apply. Valid only for those with commercial insurance. For patients covered under the medical benefit, rebate for out-of-pocket costs will be assigned directly to provider, unless patient requests direct reimbursement. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

Terms & Conditions

Bridge to Commercial Program Terms & Conditions: Eligible patients must have commercial insurance, a valid prescription for LEQVIO, and a prior authorization, predetermination, or medical exception that has been denied or pending for greater than 3 calendar days. Program provides up to two (2) doses of free medication. Program is not available to patients who are uninsured or whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program, or where prohibited by law. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Other limitations may apply. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

You can enroll your patients in 3 different ways:

Download and fax our 1-page

start form to 1-877-LEQVIO8

(1-877-537-8468)

Download the LEQVIO
Patient Start Form

Enroll your patients electronically
via ServiceCenterPortal.com for
all services, including co-pay

VISIT SERVICE
CENTER PORTAL arrow

Enroll your patients electronically
via LEQVIO-CoPayPortal.com for
co-pay–only support

VISIT
LEQVIO-COPAY PORTAL.COM arrow

LOOKING FOR MORE
INFORMATION
FOR
YOUR PATIENTS?

LEQVIO supports your practice through flexible acquisition

LEQVIO supports your practice through flexible acquisition LEQVIO supports your practice through flexible acquisition

IN-OFFICE ADMINISTRATION

Acquire LEQVIO through buy-and-bill
or an SP

BUY-AND-BILL

Administration takes place in
your office (Medical Benefit)

  • Buy-and-bill is an option for acquiring drugs covered under the medical benefit that are administered by a health care provider

  • Drugs covered under Medicare Part B (fee-for-service) must be acquired through this method

FIND OUT MORE
ABOUT BUY-AND-BILL arrow

SPECIALTY PHARMACY

Administration takes place within your office via an SP

  • A patient's plan may restrict drug coverage under the pharmacy benefit using an SP

  • LEQVIO ordered through an SP must be given to the specific patient for whom it was ordered (unlike the buy-and-bill, in which LEQVIO can be given to any patient for whom it's prescribed)

VISIT LEQVIO
SERVICE CENTER arrow

OUT-OF-OFFICE
ADMINISTRATION

Send order to an AIC, which manages
LEQVIO acquisition via buy-and-bill

ALTERNATE INJECTION CENTER (AIC)

Administration takes place at a site other than your office

  • Practice locates and refers the patient to an AIC, which then handles the following:
    - Benefits verification
    - Prior authorization support
    - Acquisition of LEQVIO
    - Administration of LEQVIO
    - Submitting claims for reimbursement

  • A system hospital outpatient department (HOPD) may act as an AIC. It's important to understand system requirements before sending the LEQVIO patient to that facility

FIND AN AIC* arrow

*May include a clinic, hospital outpatient department, or another physician's office.

INDICATION AND IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION
AND INDICATION

COLLAPSE

EXPAND

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Limitations of Use: The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity and dyspnea.

Please click here for LEQVIO full Prescribing Information.

References: 1. LEQVIO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2. Cubanski J, Damico A, Neuman T, Jacobson G. Sources of supplemental coverage among Medicare beneficiaries in 2016. KFF. November 28, 2018. Accessed November 5, 2021. https://www.kff.org/medicare/issue-brief/sources-of-supplemental-coverage-among-medicare-beneficiaries-in-2016/# 3. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 4. Data on file. Novartis Pharmaceuticals Corp; 2019. 5. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625 6. Data on file. Novartis Pharmaceuticals Corp; 2020. 7. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 8. European Medicines Agency. Annex I. Summary of Product Characteristics. Published December 9, 2020. Accessed August 4, 2022. https://www.ema.europa.eu/en/documents/product-information/leqvio-epar-product-information_en.pdf 9. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 10. Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019; 13(3):415-424. 11. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 12. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 13. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/j.jacl.2016.06.011 14. Data on file. ORION-3 (MDCO-PCS-16-01) ASCVD-only population. Novartis Pharmaceuticals Corp; 2022. 15. Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated low-density lipoprotein cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Oral presentation at: American Heart Association (AHA) Scientific Sessions 2022; November 5-7, 2022; Chicago, IL.

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity and dyspnea.

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Limitations of Use: The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.

Please click here for LEQVIO full Prescribing Information.

References: 1. LEQVIO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2. Cubanski J, Damico A, Neuman T, Jacobson G. Sources of supplemental coverage among Medicare beneficiaries in 2016. KFF. November 28, 2018. Accessed November 5, 2021. https://www.kff.org/medicare/issue-brief/sources-of-supplemental-coverage-among-medicare-beneficiaries-in-2016/# 3. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 4. Data on file. Novartis Pharmaceuticals Corp; 2019. 5. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/
ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625 6. Data on file. Novartis Pharmaceuticals Corp; 2020. 7. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 8. European Medicines Agency. Annex I. Summary of Product Characteristics. Published December 9, 2020. Accessed August 4, 2022. https://www.ema.europa.eu/en/documents/product-information/leqvio-epar-product-information_en.pdf 9. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 10. Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019; 13(3):415-424. 11. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 12. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 13. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/j.jacl.2016.06.011 14. Data on file. ORION-3 (MDCO-PCS-16-01) ASCVD-only population. Novartis Pharmaceuticals Corp; 2022. 15. Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated low-density lipoprotein cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Oral presentation at: American Heart Association (AHA) Scientific Sessions 2022; November 5-7, 2022; Chicago, IL.